Pine Haven Investment Counsel Inc Acquires 70 Shares of Johnson & Johnson $JNJ

Pine Haven Investment Counsel Inc boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% in the second quarter, Holdings Channel reports. The firm owned 8,706 shares of the company’s stock after purchasing an additional 70 shares during the quarter. Johnson & Johnson comprises about 1.0% of Pine Haven Investment Counsel Inc’s portfolio, making the stock its 23rd biggest holding. Pine Haven Investment Counsel Inc’s holdings in Johnson & Johnson were worth $1,330,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Highline Wealth Partners LLC increased its holdings in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after buying an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth approximately $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth approximately $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the first quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the first quarter worth approximately $52,000. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on JNJ shares. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a report on Friday, September 19th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. UBS Group raised their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 17th. Finally, Barclays raised their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $181.40.

Insider Buying and Selling

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $176.62 on Thursday. The company has a fifty day moving average price of $173.80 and a two-hundred day moving average price of $161.90. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The firm has a market capitalization of $425.35 billion, a PE ratio of 18.89, a P/E/G ratio of 2.25 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the business earned $2.82 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.